

# PRODUCT INFORMATION




## EP<sub>4</sub> Receptor (C-Term) Polyclonal Antibody Item No. 101775


### Overview and Properties

<b>Contents:</b>	This vial contains 500 µl of peptide affinity-purified polyclonal antibody.
<b>Synonyms:</b>	PGE <sub>2</sub> Receptor 4, Prostaglandin E <sub>2</sub> Receptor 4
<b>Immunogen:</b>	Synthetic peptide corresponding to the C-terminal region of the human EP <sub>4</sub> receptor
<b>Cross Reactivity:</b>	(+) EP <sub>4</sub> receptor; (-) EP <sub>1</sub> , EP <sub>2</sub> , and EP <sub>3</sub> receptors
<b>Species Reactivity:</b>	(+) Human, ovine, and rat; other species not tested
<b>Uniprot No.:</b>	P35408
<b>Form:</b>	Liquid
<b>Storage:</b>	-20°C (as supplied)
<b>Stability:</b>	≥3 years
<b>Storage Buffer:</b>	PBS, pH 7.2, with 50% glycerol and 0.02% sodium azide
<b>Host:</b>	Rabbit
<b>Applications:</b>	Immunohistochemistry (IHC) and Western blot (WB); the recommended starting dilution for IHC is 1:80 and 1:200 for WB. Other applications were not tested, therefore optimal working concentration/dilution should be determined empirically.

### Images



Lane 1: EP<sub>4</sub> transfected cell microsomes (5 µg)  
Lane 2: Human Jurkat lysate (30 µg)



Immunohistochemistry analysis of formalin-fixed, paraffin-embedded (FFPE) human prostate adenocarcinoma after heat-induced antigen retrieval in pH 6.0 citrate buffer. After incubation with EP<sub>4</sub> Receptor (C-Term) Polyclonal Antibody (Item No. 101775), at a 1:80 dilution, slides were incubated with biotinylated secondary antibody, followed by alkaline phosphatase-streptavidin and chromogen (DAB).

WARNING  
THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA  
This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY  
Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 11/01/2023

CAYMAN CHEMICAL  
1180 EAST ELLSWORTH RD  
ANN ARBOR, MI 48108 · USA  
PHONE: [800] 364-9897  
[734] 971-3335  
FAX: [734] 971-3640  
CUSTSERV@CAYMANCHEM.COM  
WWW.CAYMANCHEM.COM

# PRODUCT INFORMATION



## Description

---

Prostaglandin E<sub>2</sub> (PGE<sub>2</sub>) binds to four receptor subtypes: EP<sub>1</sub>, EP<sub>2</sub>, EP<sub>3</sub>, and EP<sub>4</sub>, which are all membrane-bound G protein-coupled receptors (GPCRs).<sup>1-3</sup> The EP<sub>4</sub> receptor was originally thought to be a subtype of the EP<sub>2</sub> receptor but was later found to be a distinct receptor with sequence differences.<sup>4,5</sup> It is expressed in many tissues, including the intestine, heart, kidney, lungs, and brain, and is also expressed in peripheral blood leukocytes and macrophages.<sup>3</sup> The EP<sub>4</sub> receptor is coupled to Gα<sub>s</sub>, and its activation increases intracellular cAMP levels leading to tissue-specific effects. It induces smooth muscle relaxation, angiogenesis, T cell expansion, osteoblast differentiation, and bone resorption and inhibits TNF-α production in monocytes and macrophages, among other activities. *PTGER4*, the gene encoding the EP<sub>4</sub> receptor, is overexpressed in a variety of cancers, and antagonism of the receptor in animal models inhibits tumor growth and angiogenesis.<sup>6</sup> In contrast, EP<sub>4</sub> receptor activation has anti-inflammatory and neuroprotective activities *in vitro* and in animal models.<sup>7,8</sup> Cayman's EP<sub>4</sub> Receptor (C-Term) Polyclonal Antibody can be used for immunocytochemistry (ICC), immunohistochemistry (IHC), and Western blot (WB) applications.

## References

---

1. Narumiya, S., Sugimoto, Y., and Ushikubi, F. Prostanoid receptors: Structures, properties, and functions. *Physiol. Rev.* **79**(4), 1193-1226 (1999).
2. Coleman, R.A., Eglen, R.M., Jones, R.L., *et al.* Classification of prostanoid receptors IUPHAR receptor compendium. *IUPHAR Compendium* 1-12 (1997).
3. Yokoyama, U., Iwatsubo, K., Umemura, M., *et al.* The prostanoid EP4 receptor and its signaling pathway. *Pharmacol. Rev.* **65**(3), 1010-1052 (2013).
4. Nishigaki, N., Negishi, M., Honda, A., *et al.* Identification of prostaglandin E receptor 'EP<sub>2</sub>' cloned from mastocytoma cells as EP<sub>4</sub> subtype. *FEBS Lett.* **364**(3), 339-341 (1995).
5. Regan, J.W., Bailey, T.J., Pepperl, D.J., *et al.* Cloning of a novel human prostaglandin receptor with characteristics of the pharmacologically defined EP<sub>2</sub> subtype. *Mol. Pharmacol.* **46**(2), 213-220 (1994).
6. Ching, M.M., Reader, J., and Fulton, A.M. Eicosanoids in cancer: Prostaglandin E<sub>2</sub> receptor 4 in cancer therapeutics and immunotherapy. *Front. Pharmacol.* **11**, 819 (2020).
7. Tang, E.H.C., Libby, P., Vanhoutte, P.M., *et al.* Anti-inflammation therapy by activation of prostaglandin EP4 receptor in cardiovascular and other inflammatory diseases. *J. Cardiovasc. Pharmacol.* **59**(2), 116-123 (2012).
8. Pradhan, S.S., Salinas, K., Garduno, A.C., *et al.* Anti-inflammatory and neuroprotective effects of PGE<sub>2</sub> EP4 signaling in models of Parkinson's disease. *J. Neuroimmune Pharmacol.* **12**(2), 292-304 (2017).

CAYMAN CHEMICAL  
1180 EAST ELLSWORTH RD  
ANN ARBOR, MI 48108 · USA  
PHONE: [800] 364-9897  
[734] 971-3335  
FAX: [734] 971-3640  
CUSTSERV@CAYMANCHEM.COM  
WWW.CAYMANCHEM.COM